Stay Informed

Get email alerts when new recalls match your interests.

Recall data is updated hourly from official government sources. Very recent recalls may not yet appear. About our data sources

About

We make U.S. recall data searchable and accessible for consumers and businesses.

Site

FAQ
Browse by State
Statistics
Recall Classifications
About
Enterprise API

Legal

Privacy Policy
Terms of Service
Report Incorrect Info

Official Sources

FDA Recalls ↗
USDA FSIS ↗
CPSC Recalls ↗
NHTSA Recalls ↗

RSS Feed

Home
/
Brands
/
Teva Pharmaceuticals USA

Teva Pharmaceuticals USA Recalls

All product recalls associated with Teva Pharmaceuticals USA.

Get alerts for this brand

Recall Summary

Total Recalls

1000

Past Year

303

Class I (Serious)

Most Recent

Nov 2025

Data from FDA, USDA, CPSC, and NHTSA public records. Recall counts vary by company size, industry, and reporting practices. Always check official sources for current information.

Showing 2341–2360 of 4747 recalls

Omega-3-Acid Ethyl Esters Capsules (Teva) – Unapproved API (2018)

API material used in the manufacturing of the product did not receive regulatory approval prior to release.

Class IIModerate

FDAJul 16, 2018Nationwide• Teva Pharmaceuticals USA

Valsartan Tablets (Teva) – Carcinogen Impurity (2018)

CGMP Deviations: Carcinogen impurity detected in API used to manufacture drug product.

Class IIModerate

FDAJul 16, 2018Nationwide• Teva Pharmaceuticals USA

Valsartan Tablets (Teva) – Carcinogen Impurity (2018)

CGMP Deviations: Carcinogen impurity detected in API used to manufacture drug product.

Class II

1...116 117118119 120...238

Page 118 of 238Next

Moderate

FDAJul 16, 2018Nationwide• Teva Pharmaceuticals USA

Valsartan Tablets (Teva) – Carcinogen Impurity (2018)

CGMP Deviations: Carcinogen impurity detected in API used to manufacture drug product.

Class IIModerate

FDAJul 16, 2018Nationwide• Teva Pharmaceuticals USA

Valsartan-HCTZ Tablets (Teva) – Carcinogen Impurity (2018)

CGMP Deviations: Carcinogen impurity detected in API used to manufacture drug product.

Class IIModerate

FDAJul 16, 2018Nationwide• Teva Pharmaceuticals USA

Valsartan-HCTZ Tablets (Teva) – Carcinogen Impurity (2018)

CGMP Deviations: Carcinogen impurity detected in API used to manufacture drug product.

Class IIModerate

FDAJul 16, 2018Nationwide• Teva Pharmaceuticals USA

Valsartan-HCTZ Tablets (Teva) – Carcinogen Impurity (2018)

CGMP Deviations: Carcinogen impurity detected in API used to manufacture drug product.

Class IIModerate

FDAJul 16, 2018Nationwide• Teva Pharmaceuticals USA

Valsartan-HCTZ Tablets (Teva) – Carcinogen Impurity (2018)

CGMP Deviations: Carcinogen impurity detected in API used to manufacture drug product.

Class IIModerate

FDAJul 16, 2018Nationwide• Teva Pharmaceuticals USA

Valsartan-HCTZ Tablets (Teva) – Carcinogen Impurity (2018)

CGMP Deviations: Carcinogen impurity detected in API used to manufacture drug product.

Class IIModerate

FDAJul 16, 2018Nationwide• Teva Pharmaceuticals USA

Valsartan Tablets (Teva) – Carcinogen Impurity (2018)

CGMP Deviations: Carcinogen impurity detected in API used to manufacture drug product.

Class IIModerate

FDAJul 16, 2018Nationwide• Teva Pharmaceuticals USA

Valsartan Tablets (Prinston) – Carcinogen Impurity (2018)

CGMP Deviations: Carcinogen impurity detected in API used to manufacture drug product.

Class IIModerate

FDAJul 13, 2018Nationwide• Prinston Pharmaceutical Inc

Valsartan and Hydrochlorothiazide (Prinston) – Carcinogen Impurity (2018)

CGMP Deviations: Carcinogen impurity detected in API used to manufacture drug product.

Class IIModerate

FDAJul 13, 2018Nationwide• Prinston Pharmaceutical Inc

Valsartan and Hydrochlorothiazide (Prinston) – Carcinogen Impurity (2018)

CGMP Deviations: Carcinogen impurity detected in API used to manufacture drug product.

Class IIModerate

FDAJul 13, 2018Nationwide• Prinston Pharmaceutical Inc

Valsartan and Hydrochlorothiazide (Prinston) – Carcinogen Impurity (2018)

CGMP Deviations: Carcinogen impurity detected in API used to manufacture drug product.

Class IIModerate

FDAJul 13, 2018Nationwide• Prinston Pharmaceutical Inc

Valsartan and Hydrochlorothiazide (Prinston) – Carcinogen Impurity (2018)

CGMP Deviations: Carcinogen impurity detected in API used to manufacture drug product.

Class IIModerate

FDAJul 13, 2018Nationwide• Prinston Pharmaceutical Inc

Valsartan (Prinston) – Carcinogen Impurity (2018)

CGMP Deviations: Carcinogen impurity detected in API used to manufacture drug product.

Class IIModerate

FDAJul 13, 2018Nationwide• Prinston Pharmaceutical Inc

Valsartan and Hydrochlorothiazide (Prinston) – Carcinogen Impurity (2018)

CGMP Deviations: Carcinogen impurity detected in API used to manufacture drug product.

Class IIModerate

FDAJul 13, 2018Nationwide• Prinston Pharmaceutical Inc

Valsartan (Prinston) – Carcinogen Impurity (2018)

CGMP Deviations: Carcinogen impurity detected in API used to manufacture drug product.

Class IIModerate

FDAJul 13, 2018Nationwide• Prinston Pharmaceutical Inc

Valsartan (Prinston) – Carcinogen Impurity (2018)

CGMP Deviations: Carcinogen impurity detected in API used to manufacture drug product.

Class IIModerate

FDAJul 13, 2018Nationwide• Prinston Pharmaceutical Inc

Testosterone Cypionate (Sun Pharmaceutical) – Particulate Matter (2018)

Presence of Particulate Matter: organic and inorganic compounds detected in vials of product.

Class IIModerate

FDAJul 12, 2018Nationwide• Sun Pharmaceutical Industries, Inc.